Tags

Type your tag names separated by a space and hit enter

[Pharmacological and clinical feature of rebamipide: new therapeutic targets].
Ter Arkh. 2020 Apr 27; 92(2):104-111.TA

Abstract

Rebamipide is a cytoprotector developed in Japan where it has been successfully used for the treatment of stomach diseases for 30 years. Initially discovered effects of the drug included the induction of prostaglandins and the elimination of free oxygen radicals. Recent studies discovered new therapeutic targets of the drug, its new forms that made possible using rebamipid for the treatment of such diseases as NSAID enteropathy, ulcerative colitis, radiation colitis, pouchitis, enteropathy with impaired membrane digestion. It is used in endoscopy, ophthalmology, chemotherapy, rheumatology. The aim of this review is to present current information about the pharmacological and clinical feature of rebamipide and to study its therapeutic potential.

Authors+Show Affiliations

Loginov Moscow Clinical Research Center.Loginov Moscow Clinical Research Center.Loginov Moscow Clinical Research Center.

Pub Type(s)

English Abstract
Journal Article

Language

rus

PubMed ID

32598727

Citation

Zvyaglova, M Y., et al. "[Pharmacological and Clinical Feature of Rebamipide: New Therapeutic Targets]." Terapevticheskii Arkhiv, vol. 92, no. 2, 2020, pp. 104-111.
Zvyaglova MY, Knyazev OV, Parfenov AI. [Pharmacological and clinical feature of rebamipide: new therapeutic targets]. Ter Arkh. 2020;92(2):104-111.
Zvyaglova, M. Y., Knyazev, O. V., & Parfenov, A. I. (2020). [Pharmacological and clinical feature of rebamipide: new therapeutic targets]. Terapevticheskii Arkhiv, 92(2), 104-111. https://doi.org/10.26442/00403660.2020.02.000569
Zvyaglova MY, Knyazev OV, Parfenov AI. [Pharmacological and Clinical Feature of Rebamipide: New Therapeutic Targets]. Ter Arkh. 2020 Apr 27;92(2):104-111. PubMed PMID: 32598727.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pharmacological and clinical feature of rebamipide: new therapeutic targets]. AU - Zvyaglova,M Y, AU - Knyazev,O V, AU - Parfenov,A I, Y1 - 2020/04/27/ PY - 2020/04/26/received PY - 2020/6/30/entrez KW - cytoprotector KW - disaccharidases KW - dry eye syndrome KW - enteropathy KW - oral mucositis KW - peptic ulcer disease KW - radiation colitis KW - rebamipide KW - ulcerative colitis SP - 104 EP - 111 JF - Terapevticheskii arkhiv JO - Ter. Arkh. VL - 92 IS - 2 N2 - Rebamipide is a cytoprotector developed in Japan where it has been successfully used for the treatment of stomach diseases for 30 years. Initially discovered effects of the drug included the induction of prostaglandins and the elimination of free oxygen radicals. Recent studies discovered new therapeutic targets of the drug, its new forms that made possible using rebamipid for the treatment of such diseases as NSAID enteropathy, ulcerative colitis, radiation colitis, pouchitis, enteropathy with impaired membrane digestion. It is used in endoscopy, ophthalmology, chemotherapy, rheumatology. The aim of this review is to present current information about the pharmacological and clinical feature of rebamipide and to study its therapeutic potential. SN - 0040-3660 UR - https://www.unboundmedicine.com/medline/citation/32598727/[Pharmacological_and_clinical_feature_of_rebamipide:_new_therapeutic_targets] DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.